Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Table 7

Response to second-line treatment according to the chemotherapy regimen.

Response		Second-line chemotherapy regimen				Total
		Nab-paclitaxel/Gemcitabine	FOLFIRINOX/CAPOXIRI	FOLFOX/CAPOX	Other regimens
PR	N (%)	8	9	1	3	22
		25.0	45.0	6.3	23.5	25.9
SD	N (%)	12	6	7	7	32
		37.5	30.0	43.8	41.2	37.6
PD	N (%)	12	5	8	6	31
		37.5	25.0	50.0	35.3	36.5
Total	N (%)	32	20	16	17	85
		37.6	23.5	18.8	20.0	100.0

CAPOX, oxaliplatin/capecitabine; CAPOXIRI, oxaliplatin/irinotecan/capecitabine; FOLFOX, oxaliplatin/leucovorin/5-fluorouracil; FOLFIRINOX, oxaliplatin/irinotecan/leucovorin/5-fluorouracil; PD, progressive disease; PR, partial response; SD, stable disease.